At Wilmington 1st day of November, 2013, this matter coming before the Court upon the motion to dismiss (D.I. 7) plaintiff Cumberland Pharmaceuticals Inc.'s ("Plaintiff or "Cumberland") Complaint (D.I. 1), filed by defendant InnoPharma, Inc. ("Defendant" or "InnoPharma"), and having considered the parties' papers submitted in connection therewith;
IT IS HEREBY ORDERED that Defendant's motion to dismiss (D.I. 7) is GRANTED for the reasons that follow.
1. This patent litigation action arises under the Hatch-Waxman Act. On April 4, 2012, InnoPharma notified Cumberland that it had filed an Abbreviated New Drug Application ("ANDA"), ANDA No. 200644, for a generic acetylcysteine formulation (for use in treatment of acetaminophen overdose patients). InnoPharma's letter contained a "Paragraph IV" certification contending that Cumberland's U.S. Patent No. 8, 148, 356, entitled "Acetylcysteine Composition and Uses Therefor" ("the '356 patent"), was invalid, unenforceable, or would not be infringed by InnoPharma's generic formulation. (See D.I. 1115; D.I. 8 at 5; D.I. 12 at 1)
2. On May 17, 2012, within 45 days of receipt of InnoPharma's notice letter, Cumberland filed suit for infringement, triggering an automatic 30-month stay of FDA approval of InnoPharma's ANDA. (See D.I. 12 at 1-2; 21 U.S.C. § 355(j)(B)(iii)) Cumberland alleges infringement of the '356 patent (Count I) and seeks a declaratory judgment of infringement of the '356 patent (Count II).
3. On June 8, 2012, InnoPharma filed its motion to dismiss. InnoPharma moves to dismiss the Complaint under Fed.R.Civ.P. 12(b)(1) (lack of subject matter jurisdiction), 12(b)(6) (failure to state a claim),  and 12(c) (for judgment on the pleadings). According to Defendant, all claims of the patent-in-suit cover only a formulation "free from a chelating agent, " yet the Complaint alleges that InnoPharma's product contains EDTA, which is "a chelating agent." (D.I. 8 at 1) Therefore, InnoPharma argues, its product "logically and legally cannot possibly infringe the asserted patent." (D.I. 8 at 1) Indeed, in InnoPharma's view, paragraph 16 of Cumberland's complaint states the opposite of a claim for patent infringement, alleging that "InnoPharma's product contains exactly the ingredient that the asserted patent forbids." (Id.; see also D.I. ¶16)
4. In opposing the motion, Plaintiff argues that InnoPharma improperly asks the Court to "prematurely construe terms and make factual findings that certainly are in dispute." (D.I. 12 at 10) Plaintiff contends that neither the infringement allegations contained in the Complaint, nor the patent-in-suit, are limited to an EDTA-free product. (Id. at 2) Cumberland cites to examples of cases in which courts have refused to construe disputed claim terms in connection with a motion to dismiss and have denied dismissal of patent infringement actions.
5. The Court agrees with InnoPharma that its "motion rests upon three facts, all drawn from the complaint and the asserted patent attached to the complaint, " specifically:
1. All patent claims cover only formulations "free from a chelating agent."
2. EDTA is chelating agent.
3. InnoPharma's product "contains EDTA."
(D.I. 13 at 1)
a. Independent claim 1, which is representative of all of the claims of the patent-in-suit, covers only formulations that are "free from a chelating agent, " as is seen below:
A stable aqueous pharmaceutical composition comprising between 200 and 250 mg/mL acetylcysteine, wherein the composition is free from a chelating agent, or pharmaceutical acceptable salts thereof, wherein said composition is in a suitable form for intravenous injection, wherein the pH of the composition is from 6 to 7, and wherein said composition is sealed in an airtight container comprising a fill volume of said composition and a headspace volume occupied by a pharmaceutically inert gas.
('356 patent at col. 9, lines 17-25) (emphasis added) No formal process of claim construction is necessary in order to determine that "free from a chelating agent" means that a claimed composition may not include a chelating agent. Cumberland does not even suggest how "free from a chelating agent" could be construed to cover a composition containing a chelating agent. Indeed, to the contrary, the patent explains that the inventor developed a composition distinct from a prior art formulation in that the "old" formulation contained a chelating agent while the "new" formulation does not. (See, e.g., '356 patent, Abstract ("This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA."); id, Summary of the Invention, col. 2, lines 45-50 ("It has been surprisingly found that an aqueous composition containing acetylcysteine, sterilized water, and a pH-adjusting agent, is stable without the addition of a chelating agent. Thus, the present invention relates to a solution containing acetylcysteine, which is substantially free of chelating agents.")) Likewise, the Complaint explains that Cumberland moved from an "old formulation" containing EDTA to a "new formulation" that does not. (See D.I. ...